Novo CEO Willing To Testify On Weight-Loss Drugs After Sanders Threatens To Subpoena Novo President

By Maaisha Osman / June 11, 2024 at 5:26 PM
The Senate health committee will vote next week on whether to subpoena Novo Nordisk President Doug Langa to testify on why the company charges high U.S. prices for its type-2 diabetes and obesity drugs, Ozempic and Wegovy, an escalation of Chair Bernie Sanders’ (I-VT) efforts to demand lower prices for the drugs. A Novo Nordisk spokesperson tells Inside Health Policy that its global CEO Lars Fruergaard Jørgensen, who is better versed in reference pricing, is willing to testify, and...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.